Upper Respiratory Tract Infection Treatment Market Size, Share, By Type (Topical treatment, and Drug Treatment), By Application (Hospital Pharmacies, Retail Pharmacies and Drug Stores, and Online Pharmacies), and By Region - Trends, Analysis and Forecast till 2034

Report Code: PMI238919 | Publish Date: March 2024 | No. of Pages: 182

Global Upper Respiratory Tract Infection Overview

Upper Respiratory Tract Infection Treatment Market was valued at US$ 1.9 Billion in 2024 and is projected to grow at a CAGR of 3.6% to reach US$ 2.7 Billion by 2034.

Inflammation and edoema of the upper airways that is self-limited and associated with coughing are the hallmarks of upper respiratory tract infections. Large airways such as the nose, sinuses, pharynx, and larynx are all affected by upper respiratory tract infections. Upper respiratory tract infections can be caused by a variety of viruses and bacteria. Numerous patient illnesses, such as acute bronchitis, the common cold, influenza, and respiratory distress syndromes, are brought on by them.

Future market growth for upper respiratory tract infections is anticipated to be fueled by the rising prevalence of chronic upper respiratory tract infections globally. As reported by Lancet In 2019, there were 17.2 billion incident cases of URIs (Upper Respiratory Tract Infection), accounting for 42.83 percent (40.01 to 45.77 percent) of all cases in the GBD 2019 research. The World Health Organization's Mortality Database indicates that the 75 and older age group has the highest death rate and the increase in elderly populations in most of the regions who are vulnerable to diseases may also contribute to the growth of the target market.

Global Upper Respiratory Tract Infection Dynamics

Increase in OTC Medicine consumption

The Market for Upper Respiratory Infections Treatment is anticipated to grow quickly due to the rapid rise in OTC drug and medicine usage in everyday life. OTC medication is defined as over-the-counter medication that can be bought without a prescription. Patients with a common cold and cough frequently avoid seeing a doctor since they can treat the infection on their own with over-the-counter medications due to the worldwide increase in upper respiratory tract infection over the past few decades. It has caused the consumption of OTC pharmaceuticals to expand quickly and is anticipated to support the target market's future expansion.

Increase in Number of Drugs in Pipeline and New Investments

Upper Respiratory Tract Infection Market Growth is anticipated as a result of the presence of numerous drugs in the pipeline, with new formulations to treat both common diseases associated with upper respiratory tract infections as well as new types of diseases. Drugs in the Pipeline, for instance, include MK7264 from Merck & Co., PT010 from AstraZeneca, and Relenza from GlaxoSmithKline. Additionally, it is anticipated that strategic development, fresh investment in the industry, and startups developing drugs with greater efforts will increase market competitiveness, likely resulting in the expansion of the target market.

Rapid Growth in Number of Generic Medicines

The market growth for upper respiratory tract infections is anticipated to be constrained during the forecast period by the rise in generic manufacturer and distributor numbers. The majority of the population prefers generic medications over branded ones since they are more affordable and accessible.

For instance, March 2023, according to the Times of India, Indian retail pharmacy market is dominated by generic drugs, making up for 70 to 80% and demand is increasing over years especially in geriatric population. Several initiatives gas been taken by Indian government for endorsement for generic drugs availability for example “Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) which can Expand Generic Drug Range in coming years.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global Upper Respiratory Tract Infection Segmentation

Upper Respiratory Tract Infection Treatment Market is segmented based on Type, Application and Region.

Type Insight

On the basis of Type, Upper Respiratory Tract Infection Treatment Market is segmented into Topical treatment, and Drug Treatment. Topical treatment segment is expected to dominate the target market growth because this method of treatment is implemented directly through nasal route which has higher chances of better effects in human health.

Application Insights

On the basis of Application, Upper Respiratory Tract Infection Treatment Market is segmented into Hospital Pharmacies, Retail Pharmacies and Drug Stores, and Online Pharmacies.  Retail pharmacies are expected to dominate the target market growth due to their wide spread and ease to access, majority of population tend to consume medication without Doctor’s prescription.

Regional Insights:

On the basis of region, the Upper Respiratory Tract Infection Treatment Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to factors such as Growing demand for Over-The-Counter medications, a strong distribution network for pharmacies, and an increase in the frequency of chronic respiratory tract infections are expected to drive growth in the Global Upper Respiratory Tract Infection Treatment market in the Region.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Upper Respiratory Tract Infection Treatment Market Report Scope:

Attribute

Details

Base year for estimation

2023

Forecast period

2024 – 2034

Market representation

Revenue in USD Billion & CAGR from 2024 to 2034

Market Segmentation

By Type - Topical treatment, Drug Treatment

By Application - Hospital Pharmacies, Retail Pharmacies Drug Stores, and Online Pharmacies

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the Upper Respiratory Tract Infection Treatment Market report based on Type, Application and Region:

Upper Respiratory Tract Infection Treatment Market, By Type:

  • Topical treatment
  • Drug Treatment

Upper Respiratory Tract Infection Treatment Market, By Application:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Upper Respiratory Tract Infection Treatment Market, By Region:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East & Africa

Global Upper Respiratory Tract Infection Key Players

The key players operating the Upper Respiratory Tract Infection Treatment Market includes, GlaxoSmithKline Plc., Alcon, Merck & Co., Inc., Regeneron Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Collegium Pharmaceutical, GlaxoSmithKline plc, Verona Pharma Plc, Pfizer Inc, Teva Pharmaceuticals, Hospira.

Global Upper Respiratory Tract Infection Company Profile

  • GlaxoSmithKline Plc.*
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Alcon
  • Merck & Co., Inc.,
  • Regeneron Pharmaceuticals Inc.,
  • Teva Pharmaceutical Industries Ltd.
  • Collegium Pharmaceutical
  • GlaxoSmithKline plc
  • Verona Pharma Plc
  • Pfizer Inc
  • Teva Pharmaceuticals
  • Hospira

“*” marked represents similar segmentation in other categories in the respective section.

Global Upper Respiratory Tract Infection Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Preview
    • Executive Summary
    • Key Findings—Global Outlook for medical carts Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Type
      • Market Snippet, By Application
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restrains
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Market Segmentation, By Type
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Segment Trends
    • Topical treatment
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Drug Treatment
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
  6. Market Segmentation, By Application, 2022 – 2032, (US$ Bn)
    • Overview                                      
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Segment Trends
    • Hospital Pharmacies
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Retail Pharmacies & Drug Stores
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Online Pharmacies
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
  7. Global Market, By Region, 2022 – 2032, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Application, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Application, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Application, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Application, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Application, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  2. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  3. Company Profiles
  • GlaxoSmithKline Plc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Alcon
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Merck & Co., Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Regeneron Pharmaceuticals Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Collegium Pharmaceutical
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Verona Pharma Plc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Hospira
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  1. The Last Word
    • Future Impact
    • About Us
    • Contac

FAQs

The Upper Respiratory Tract Infection Treatment Market is segmented into Type, Application and Region.

Upper Respiratory Tract Infection Treatment Market is driven by factors like increase in incidences of chronic upper respiratory tract infection, increase in demand for OTC medication and increase in number of drugs in pipeline.

By region, the Upper Respiratory Tract Infection Treatment Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period.

The key players operating the Upper Respiratory Tract Infection Treatment Market includes GlaxoSmithKline Plc., Alcon, Merck & Co., Inc., Regeneron Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Collegium Pharmaceutical, GlaxoSmithKline plc, Verona Pharma Plc, Pfizer Inc, Teva Pharmaceuticals, Hospira.

Upper Respiratory Tract Infection Treatment Market was valued at US$ 1.9 Billion in 2024 and is projected to grow at a CAGR of 3.6% to reach US$ 2.7 Billion by 2034.